IGAM
NBIX icon

iA Global Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

iA Global Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,800
Closed -$823K – 435
2025
Q4 		$823K Buy
5,800
+585
+11% +$84.8K 0.01% 308
2025
Q3 		$732K Buy
+5,215
New +$707K 0.01% 319
2024
Q4 		– Sell
-2,652
Closed -$306K – 486
2024
Q3 		$306K Buy
+2,652
New +$364K 0.01% 440
2024
Q2 		– Sell
-1,410
Closed -$194K – 503
2024
Q1 		$194K Sell
1,410
-177
-11% -$24.2K ﹤0.01% 440
2023
Q4 		$209K Buy
+1,587
New +$183K ﹤0.01% 431

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

iA Global Asset Management's NBIX Position: Q1 2026 in Review

iA Global Asset Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 5,800 shares — an estimated $823K sold.

iA Global Asset Management first reported a position in NBIX in Q4 2023 and held it in 5 quarters. The position peaked at $823K in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • iA Global Asset Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • iA Global Asset Management sold 5,800 Neurocrine Biosciences shares in Q1 2026, an estimated $823K.
  • iA Global Asset Management first reported a position in Neurocrine Biosciences in Q4 2023 and held it in 5 quarters.
  • iA Global Asset Management's Neurocrine Biosciences position peaked at $823K in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on iA Global Asset Management's 13F filing for Q1 2026, filed 23 Apr 2026.